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Ciprofloxacin is used in neonates with suspected or documented Gram-negative serious infections. Currently, its use is off-label
partly because of lack of pharmacokinetic studies. Within the FP7 EU project TINN (Treat Infection in NeoNates), our aim was
to evaluate the population pharmacokinetics of ciprofloxacin in neonates and young infants<3 months of age and define the
appropriate dose in order to optimize ciprofloxacin treatment in this vulnerable population. Blood samples were collected from
neonates treated with ciprofloxacin and concentrations were quantified by high-pressure liquid chromatography–mass spec-
trometry. Population pharmacokinetic analysis was performed using NONMEM software. The data from 60 newborn infants
(postmenstrual age [PMA] range, 24.9 to 47.9 weeks) were available for population pharmacokinetic analysis. A two-compart-
ment model with first-order elimination showed the best fit with the data. A covariate analysis identified that gestational age,
postnatal age, current weight, serum creatinine concentration, and use of inotropes had a significant impact on ciprofloxacin
pharmacokinetics. Monte Carlo simulation demonstrated that 90% of hypothetical newborns with a PMA of<34 weeks treated
with 7.5 mg/kg twice daily and 84% of newborns with a PMA>34 weeks and young infants receiving 12.5 mg/kg twice daily
would reach the AUC/MIC target of 125, using the standard EUCASTMIC susceptibility breakpoint of 0.5 mg/liter. The associ-
ated risks of overdose for the proposed dosing regimen were<8%. The population pharmacokinetics of ciprofloxacin was evalu-
ated in neonates and young infants<3 months old, and a dosing regimen was established based on simulation.
Ciprofloxacin, a synthetic fluoroquinolone, can be used to treatsepsis caused by multiple resistant organisms (1). It is not
considered a first-line treatment in current guidelines for neonatal
sepsis but is used in severe infections caused by Enterobacter spp.
resistant to standard treatment and when there is a major risk of
meningitis and secondary cerebral abscess (2, 3). In a recent Euro-
pean survey, ciprofloxacin was used “off-label” in 25% of neonatal
intensive care units,mainly in cases of culture-provenbacterial sepsis
due tomultidrug-resistant organisms that are sensitive to ciprofloxa-
cin (4).
After intravenous administration, ciprofloxacin is widely distrib-
uted inmost bodily fluids and tissues, with a high penetration in the
cerebrospinal fluid (CSF) and central nervous system. Glomerular
filtration and tubular secretion are the main mechanisms of renal
excretion, and65% of ciprofloxacin is excreted unchanged by the
kidney (5). In adults, the area under the concentration-time curve
from0 to 24 h (AUC024)/MIC ratio appears to be the best predictor
of microbiological and clinical outcome. A target AUC024/MIC
valueof125was required for treatingGram-negative infections (6, 7).
Since data in neonates are limited, the present study was con-
ducted to assess the population pharmacokinetics of ciprofloxacin in
neonates andyoung infants3monthsof ageand touse thesedata to
calculate an optimal dosing regimen of ciprofloxacin for use in these
patients.
MATERIALS AND METHODS
Study design. The trial was a prospective, open label pharmacokinetic
study of ciprofloxacin, conducted in the neonatal intensive care unit of the
Liverpool women’s hospital and in the pediatric intensive care unit of the
Alder Hey Children’s Hospital, Liverpool, United Kingdom. Inclusion
and exclusion criteria are presented in Fig. 1. The study was approved by
the institutional ethics board and independent ethics board of the TINN
project (EudraCT 2010-019955-23). It was alsomonitored by an indepen-
dent safety monitoring board (DSMB).
Dosing regimen and pharmacokinetic sampling. Ciprofloxacin (ge-
neric; Peckforton Pharmaceuticals, Crewe, United Kingdom) was admin-
istered as an intravenous infusion either over either 30 or 60min by using
a syringe pump connected tomicrobore tubing at a dose of 10mg/kg/dose
twice daily (BID) for neonates with a postmenstrual age (PMA) of 40
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weeks and three times daily (TID) or BID for young infants with a PMAof
40 weeks.
Ciprofloxacin pharmacokinetics was assessed on day 1 (D1) or D2 of
treatment and again between D5 and D7. The total number of study-
specific blood samples was restricted to six per participant with a maxi-
mum of three on each sampling day. Patients were randomly assigned to
one of the two predefined three-time point schedules (Table 1). Precise
infusion and sample times were recorded. The blood volume of samples
obtained for pharmacokinetic analyses was 0.2 ml per sample. Scavenged
samples were also obtained from blood remaining after routine biochem-
ical tests. Only samples with validated sampling information were in-
cluded. Blood samples were refrigerated and centrifuged (2,500 g at 4C
for 10 min), and serum or plasma was stored at 70°C. Samples were
shipped ondry ice to theDepartment of Pediatric Pharmacology at Robert
Debré Hospital, where they were stored at70°C prior to analysis.
Analytical method of ciprofloxacin and creatinine. The analytical
method of ciprofloxacin has been reported previously (8). Briefly, cipro-
floxacin concentrations were determined using high-performance liquid
chromatography with mass spectrometry with ciprofloxacin-d8 as an in-
ternal standard. The calibration curve ranged from 25 to 3,000 ng/ml. The
inter- and intraday coefficients of variation of controls were 4.1 and 2.4%,
respectively. The lower limit of quantification was 25 ng/ml. Serum cre-
atinine concentrations were measured by an adapted Jaffé method using
the Architect C system (Abbott Diagnostics, Abbott Park, IL).
Population pharmacokineticmodeling of ciprofloxacin. Pharmaco-
kinetic analysis was carried out using the nonlinear mixed effects model-
ing programNONMEMv7.2 (IconDevelopment Solutions, SanAntonio,
TX). First-order conditional estimationmethodwith interactionwas used
to estimate pharmacokinetic parameters and their variability.
The interindividual variability of the pharmacokinetic parameters was
estimated by using an exponential model and was expressed as follows:
i mean*e
i, where i represents the parameter value of the ith subject,
mean is the typical value of the parameter in the population, and i is the
variability between subjects, which is assumed to follow a normal distri-
bution with a mean of zero and variance 	2.
Covariate analysis followed a forward and backward selection process.
The likelihood ratio test was used to test the effect of each variable on
model parameters. The effects of current weight, birth weight, gestational
age, postnatal age, postmenstrual age, serum creatinine concentration
(collectedwithin48 h of pharmacokinetic sampling), and comedication
were investigated as potential variables affecting pharmacokinetic param-
eters. During the first step of covariate model building, a covariate was
included if a significant (P  0.05, 
2 distribution with one degree of
freedom) decrease (reduction  3.84) in the objective function value
(OFV) from the basic model and a reduction in the variability of the
pharmacokinetic parameter were obtained. All of the significant covari-
ates were then added simultaneously into a “full” model. Subsequently,
each covariate was independently removed from the full model. If the
increase in the OFVwas higher than 6.635 (P 0.01, 
2 distribution), the
covariate was considered significantly correlated with the pharmacoki-
netic parameter and was therefore retained in the final model.
Model validationwas based on graphical and statistical criteria. Good-
ness-of-fit plots, including observed (DV) versus population prediction
(PRED), DV versus individual prediction (IPRED), conditional weighted
residuals (CWRES) versus time, and CWRES versus PRED, were initially
used for diagnostic purposes (9). The stability and performance of the
final model was also assessed bymeans of a nonparametric bootstrap with
resampling and replacement. Resampling was repeated 500 times, and the
values of estimated parameters from the bootstrap procedure were com-
pared to those estimated from the original data set. The entire procedure
was performed in an automated fashion, using PsN (v2.30) (10). The final
model was also evaluated graphically and statistically by normalized pre-
diction distribution errors (NPDE) and prediction-corrected visual pre-
dictive check (pcVPC) (11, 12). One-thousand data sets were simulated
using the final population model parameters. The NPDE results were
summarized graphically by default as provided by the NPDE R package
(v1.2) (13): (i) QQ-plot of theNPDE and (ii) histogramof theNPDE. The
NPDE is expected to follow an “N(0,1)” distribution. For pcVPC, ob-
FIG 1 Inclusion and exclusion criteria.
TABLE 1 Pharmacokinetic sampling schedule
Group Sampling timea
Ciprofloxacin administered
twice daily
A End of infusion* T3 T8
B T2 T6 T12
Ciprofloxacin administered
three times daily
C End of infusion* T3 T8
D T2 T4 T8
a The sampling times are indicated with reference to the start of ciprofloxacin infusion.
*, For infants weighing1,000 g, samples were taken randomly on two specific times to
minimize blood loss and to ensure representation of each period.
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served and simulated dependent variables were normalized based on the
typical population prediction for the median independent variable in the
bin. The 95% confidence intervals for the median and the 5th and 95th
percentiles of the prediction-corrected simulated concentrations were
calculated, plotted against the time, and compared to the prediction-cor-
rected observed concentrations.
Ciprofloxacin penetration into the CSF. Assessment of the cipro-
floxacin penetration into the CSF was evaluated by the CSF/serum cipro-
floxacin concentration ratio. Because serum ciprofloxacin concentrations
were not obtained concurrently with CSF sample collection, serum con-
centrations at the time of CSF sample collectionwere calculated via Bayes-
ian estimation using the final model.
Dosing regimen optimization. Monte Carlo simulations were per-
formed using the parameter estimates obtained from the final model in
order to define optimal dosing regimen able to attain the target AUC/MIC
value of 125 h in ca. 80%of patients. To ensure comparable safety profiles,
the percentage of patients below the reported maximum AUC was also
considered. The pediatric dose of ciprofloxacin was simulated on amg/kg
basis according to different age groups. Thus, various mg/kg dosing regi-
mens (5, 7.5, 10, 12.5, and 15 mg/kg/dose BID) were simulated in each
neonatal group. One-thousand simulations were performed using the
original data set, and AUC024 at steady state was calculated for each
simulated patient. The target attainment rate was then calculated for each
dosing regimen to define the optimal dose regimen in each neonatal
group.
RESULTS
Study population. Sixty-four patients were initially included
from February 2011 to June 2012. All of the patients fulfilled the
inclusion and exclusion criteria, and informed consent was ob-
tained from all patients. Four patients were excluded from the
pharmacokinetic analysis for the following reasons: two patients
were withdrawn from the study, one patient was treated with di-
alysis, and one patient received ciprofloxacin within 36 h of inclu-
sion. Finally, 60 newborns were included for the population phar-
macokinetic analysis. Of these, 7 received ciprofloxacin at 5 mg/
kg/dose BID, 6 were administered ciprofloxacin at 10 mg/kg/dose
TID, and 47 were given ciprofloxacin at 10 mg/kg/dose BID. No
patients discontinued the ciprofloxacin treatment due to adverse
events, and no drug-related adverse events were shown to have a
causal associationwith ciprofloxacin therapy. The trial flow is pre-
sented in Fig. 2.
The mean the standard deviation postmenstrual age (PMA)
and weight of the 60 patients at the time of study were 35.7 6.5
weeks (range, 24.9 to 47.9) and 2,060  1,020 g (range, 700 to
4,200 g), respectively. The PMA and current weight were all nor-
mally distributed (P 0.4 andP 0.2, respectively [Kolmogorov-
Smirnov test]). A summary of patient characteristics is presented
in Table 2.
Model building. For population modeling, 430 ciprofloxacin
concentrations (265 pharmacokinetic and 165 scavenged sam-
ples) were available. The ciprofloxacin concentrations of pharma-
cokinetic and scavenged samples ranged from 450 to 15,976 and
from 52 to 10,961 ng/ml, respectively. The concentration versus
time profile is shown in Fig. 3.
A two-compartment model with first-order elimination fitted
the data. The OFV value and residual variability of the two-com-
partment model were lower than those of the one-compartment
FIG 2 Trial flow chart.
TABLE 2 Baseline characteristics in 60 neonates and infants
Characteristicsa
No. of
patients Mean (SD) Median (range)
Total patients 60
Gender (male/female) 39/21
Race (Caucasian/Asian/
unknown)
53/5/2
IUGR 3
GA (wks) 30.4 (5.8) 27.9 (23.3–42.0)
PMA (wks) 35.7 (6.5) 36.5 (24.9–47.9)
PNA (days) 38 (30) 27 (5–121)
Birth wt (g) 1,518 (884) 1,115 (540–3850)
Current wt (g) 2,060 (1020) 1,955 (700–4200)
Serum creatinine concn
(mol/liter)
52 (32) 41 (22–164)
Ciprofloxacin treatment
Duration (days) 5 (4) 5 (1–17)
Dose (mg/dose) 18.9 (10.1) 18.7 (4.5–40.0)
Dose (mg/kg/dose) 9.1 (1.6) 9.7 (4.4–11.0)
Comedication
Inotropic agents 22
Teicoplanin 41
Diuretics 30
Caffeine 15
Amoxicillin-clavulanic acid 12
Nystatin 12
Colistin-tobramycin-
amphotericin B
10
a IUGR, intrauterine growth restriction; GA, gestational age at birth; PMA,
postmenstrual age; PNA, postnatal age.
FIG 3 Ciprofloxacin concentrations versus time. The solid line represents the
population prediction of a typical patient.
Zhao et al.
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model. The model was parameterized in terms of the central vol-
ume of distribution (V1), the peripheral volume of distribution
(V2), the intercompartment clearance (Q), and the clearance (CL)
of ciprofloxacin. Interindividual variability was best described by
an exponential model and was then estimated for V1, V2, and CL.
Interoccasion variability on CL was coupled to interindividual
variability by an additive model, respectively. A proportional
model best described residual variability.
Covariate analysis. The allometric size approach was used by
incorporating a priori the current weight into the basic model
(allometric coefficients of 0.75 for CL and Q and of 1 for V1 and
V2), which caused a significant drop in the OFV of 113.9 points.
Postmenstrual age was identified as the most important covariate
on CL, associated with a drop in the OFV of 55.6 U. However,
gestational age and postnatal age together proved to be superior
(OFV 66.7 U) to postmenstrual age alone. A further decrease in
the OFV of 17.1 U was achieved by implementing the serum cre-
atinine concentration on clearance. The model was further im-
proved by introducing the coadministration of inotropic agents
(OFV 7.5 U) as a third covariate on clearance. For V1, only the
coadministration of inotropic agents caused a significant drop in
theOFVof 3.9 points in the forward selection process. However, it
was not retained in the model after the backward selection pro-
cess. A detailed presentation of the covariate analysis results is
presented in Table 3. Size explained 31.2%, renal maturation ex-
plained 25.6%, renal function explained 5.7%, and coadministra-
tion of inotropic agents explained 2.4% of the ciprofloxacin CL
variability. The  shrinkages were 5.4% for CL, 25.7% for V1, and
25.0% for V2, respectively. The ε shrinkage was 13.6%.
Table 4 summarizes parameter estimates of the final pharmacoki-
neticmodel. Themedian (range)of estimatedweight-normalizedCL
and volume distribution at steady state (sumofV1 andV2) were 0.20
(0.04 to 0.81) liters/h/kg and2.02 (0.40 to 3.55) liters/kg, respectively.
The AUC024 at steady state for the evaluated dose regimen ranged
from 35 to 291mg·h/liter. Ciprofloxacin CL increased allometrically
with current weight in neonates and young infants, decreased with
increasingcreatinine concentration, and showeda29%decreasewith
the coadministration of inotropic agents. The relationship between
ciprofloxacinweight-normalizedCL(liters/kg) versuspostmenstrual
age is shown in Fig. 4.
TABLE 3 Covariate analysis
Characteristica
Pharmacokinetic
parameter(s)
Objective function
value
IIVb CL
(%)
Structural model 6,569.0c 98.3
Allometric model CL, V1, V2, Q
Current body wt 6,455.1 67.6
Impact of age V1
GA 6,454.9
PNA 6,451.9
PMA 6,453.2
Impact of age V2
GA 6,455.1
PNA 6,452.3
PMA 6,453.7
Impact of renal maturation CL
Birth wt 6,442.0
GA 6,438.7
PNA 6,425.2
PMA 6,399.5 43.6
Birth wt and PNA 6,396.2
GA and PNA 6,388.4 42.5
Impact of renal function CL
Serum creatinine 6,429.3
Impacts of renal maturation and renal function CL
GA, PNA, and serum creatinine 6,371.3 36.9
Impacts of renal maturation, renal function, and comedication CL
GA, PNA, serum creatinine, and diuretics 6,371.4
GA, PNA, serum creatinine, and caffeine 6,369.2
GA, PNA, serum creatinine, and teicoplanin 6,371.0
GA, PNA, serum creatinine, and amoxicillin-clavulanic acid 6,366.8
GA, PNA, serum creatinine, and nystatin 6,370.9
GA, PNA, serum creatinine, and inotropic agents 6,363.8 34.5
a GA, gestational age; PNA, postnatal age; PMA, postmenstrual age.
b IIV, interindividual variability.
c OFV values of model with significant improvement are indicated in boldface.
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Model evaluation. Model diagnostics showed acceptable good-
ness-of-fit for the final model of ciprofloxacin. As shown in Fig. 5A
and B, the predictions are unbiased. In the diagnostic plots of
CWRES versus time and PRED, no trends were observed (Fig. 5C
and D). In addition, the median parameter estimates resulting
from the bootstrap procedure closely agreed with the respective
values from the final population model, indicating that the final
model is stable and can redetermine the estimates of population
pharmacokinetic parameters (Table 4). The NPDEs are presented
in Fig. 5E and F. NPDE distribution and histogram met well the
theoreticalN(0,1) distribution and density, indicating a goodfit of
the model to the individual data. The mean and variance of the
NPDE were 0.05 (Wilcoxon signed-rank test, P 0.19) and 0.91
(Fisher variance test, 0.17), respectively. The pcVPC is shown in
Fig. 5G. The prediction-corrected observed concentrations fit well
the simulated concentrations, confirming the predictive perfor-
mance of the developed model.
Ciprofloxacin penetration into the CSF. The concentra-
tions of ciprofloxacin in six CSF samples ranged from 187 to
1,650 ng/ml, respectively. The median value of CSF/serum
concentration ratio was 0.32 (range, 0.08 to 0.58). A trend for
correlation between the CSF collection time and the CSF/
serum concentration ratios was demonstrated, suggesting less
elimination from (or diffusion in) the CSF than the systemic
circulation (Fig. 6).
Dosing regimenoptimization.The target attainment rates as a
function of dose and age groups for a standardMIC susceptibility
breakpoint of 0.5 mg/liter are shown in Fig. 7. A cutoff point of a
PMA of 34 weeks was selected to separate age groups based on
visual inspection of the plot showing CL versus PMA (Fig. 4).
A total of 90% of simulated newborns with a PMA of 34
weeks and 84% of newborns with a PMA of34 weeks achieved
the target AUC/MIC values of 125 h when treated at doses of 7.5
and 12.5mg/kg BID, respectively. The associated risks of overdose
(AUC 291mg·h/liter, themaximal value reported in the present
study, did not show short-term adverse events) for the proposed
dosing regimen were8%. Higher doses will be required for pa-
tients with more resistant bacterial strains.
TABLE 4 Population pharmacokinetic parameters of ciprofloxacin and bootstrap results
Parametera
Full data set Bootstrap
Final estimate RSE (%) Median 5th–95th percentile
V1 (liters)
V1 1 (CW/1955)
1 1.97 17.7 1.82 0.78–2.59
V2 (liters)
V2 2 (CW/1955)
2 1.93 21.9 1.97 1.38–3.02
Q (liters/h)
Q 3 (CW/1955)0.75
3 2.5 32.6 2.62 1.02–5.41
CL (liters/h)
CL 4 (CW/1955)0.75 Fage RF Finotrope
4 0.366 6.0 0.365 0.323–0.407
Fage (GA/27.9)
5 (PNA/27)6
5 2.11 11.9 2.09 1.60–2.57
6 0.494 10.8 0.492 0.386–0.606
RF EXP[(CREA-42) 7]
7 0.00335 46.0 0.00331 0.00753 to0.00063
Finotrope
8 0.708 10.9 0.719 0.572–0.869
Interindividual variability (%)
V1 48.1 63.6 49.6 26.2–77.2
V2 49.3 68.3 51.2 15.8–76.9
CL 33.2 19.9 31.3 25.3–37.4
Interoccasion variability (%)
CL 16.4 55.6 16.6 9.2–26.2
Residual variability (%) 19.3 28.2 18.7 14.8–23.1
a V1, central volume of distribution; V2, peripheral volume of distribution; Q, intercompartment clearance; CL, clearance; RF, renal function; CW, current weight in grams;
Finotrope, scaling factor applied for patients coadministered with inotropic agents; CREA, serum creatinine concentration in mol/liter; GA, gestational age in weeks; PNA, postnatal
age in days. In our population, 1,955 g, 27.9 weeks, 27 days, and 42 mol/liter were the median current weight (at the day of the study), gestational age, postnatal age, and serum
creatinine concentration values, respectively.
Zhao et al.
6576 aac.asm.org Antimicrobial Agents and Chemotherapy
DISCUSSION
This is the first population pharmacokinetic study of ciprofloxa-
cin conducted in a cohort of neonates and young infants. It was
undertaken to estimate ciprofloxacin pharmacokinetic parame-
ters and to evaluate the impact of demographic, clinical, and bio-
logical factors on ciprofloxacin disposition. Our results show that
a two-compartment model with first-order elimination with ges-
tational age, postnatal age, current weight, serum creatinine con-
centration, and coadministration of inotropic agents was optimal
for data modeling.
Ciprofloxacin is a fluoroquinolone targeting bacterial DNA
gyrase enzyme, a member of the class of type II topoisomerases
that displays in vitro activity against most Gram-negative and
many Gram-positive pathogenic bacteria, many of which are re-
sistant to a wide range of antibiotics. Ciprofloxacin has a complex
safety profile. A range of adverse drug reactions, including ar-
thropathies, without identified long-term effects, need to be bal-
anced with its efficacy (14–16). Potential neuroprotective effects
were demonstrated in a juvenile animal model subjected to Esch-
erichia coli sepsis (17). Increase in multidrug-resistant sepsis
forces the use of ciprofloxacin (18, 19). However, dosages vary
widely from one country to another and from one center to an-
other within the same country (4), since only a few pharmacoki-
netic studies have been conducted in preterm and term neonates
(20–22). Since ciprofloxacin is mainly eliminated by the renal
route, renal anatomical and functional maturation is expected to
have a major influence on ciprofloxacin clearance and dosing in
neonates and young infants.When the currentweight is taken into
account using an allometric scaling approach, the independent
impact of gestational and postnatal ages on clearance illustrates
the influence of both antenatal and postnatal renal maturation on
ciprofloxacin clearance (Fig. 8); this includes the expected conse-
quences of the normal pattern of renal function ontogeny (23).
Renal function, as reflected by serum creatinine concentra-
tions, was significantly and independently correlated with cipro-
floxacin clearance in the present study. The relation of serum cre-
atinine to the glomerular filtration rate (GFR) at birth is
complicated. There was no unique equation to describe the rela-
tionship between renal function and drug clearance in neonates.
We have demonstrated that the variation in the serum creatinine
measurement had a considerable impact on the transferability of a
published creatinine-based dosing regimen of renal excreted drug
to different clinical settings (24). The influence of residual mater-
nally derived creatinine seems to be limited in our study, since
neonates at5 days of age were included. Ciprofloxacin clearance
decreased with the coadministration of inotropic drugs. A possi-
ble explanation is that inotropic agents are often given when there
is decreased blood pressure, which will result in decreased GFR.
The same effect was observed by Seay et al. (25), who reported that
the coadministration of dopamine induced a 28%decrease in van-
comycin clearance in neonates. The use of inotropic agentsmay be
also a surrogate for underlying hemodynamic instability and al-
tered renal hemodynamics, resulting in decreased drug elimina-
tion, as suggested by previous investigators (25). We were unable
to demonstrate any significant effect of ventilation or intrauterine
growth retardation on ciprofloxacin disposition. Clearly, the im-
pact of these variables on ciprofloxacin neonatal pharmacokinet-
ics is complex, probably even more in critically ill neonates. In
addition, our study is probably not able to demonstrate their full
impact.
In adults, the best surrogate for the ciprofloxacin pharmacoki-
netic-pharmacodynamic relationship is the AUC024/MIC ratio.
A target AUC024/MIC value of 125 hwas required against Gram-
negative infections (6, 7). According to regulatory guidelines (26–
28), the pharmacokinetic-pharmacodynamic relationship for most
anti-infective drugs can be assumed to be similar across all age
groups, includingneonates,makingciprofloxacinagoodexample for
demonstrating thatmodelingandsimulationapproaches canbeused
to establish optimal dosage recommendations in neonates. Dosage
administration in neonates is commonly based on an mg/kg basis
according to thedifferentagegroups (pretermor termneonates), and
a standardmg/kg dose is calculated accordingly in each group. In the
present study and in order to reach “optimal but practical dosage
recommendations” for clinicians, two groups of patients were de-
fined, newborns with a PMA of34 weeks or a PMA of34 weeks,
and thedose required to achieve thepredefinedAUC/MIC targetwas
adapted to body weight (i.e., in mg/kg) in the two age groups. The
simulation approach demonstrates that doses of 7.5 mg/kg for new-
FIG 4 Ciprofloxacin CL versus PMA.
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FIG 5 Model evaluation for ciprofloxacin. (A) Population predicted (PRED) versus observed concentrations (DV); (B) individual predicted (IPRED) versus DV; (C)
conditional weighted residuals (CWRES) versus time; (D) CWRES) versus PRED; (E) QQ-plot of the distribution of the normalized prediction distribution errors
(NPDE) versus the theoretical N(0,1) distribution; (F) histogram of the distribution of the NPDE, with the density of the standard Gaussian distribution overlaid; (G)
prediction-corrected visual predictive check. The circles represent the prediction-corrected observed concentrations. The solid line represent the median prediction-
corrected observed concentrations and semitransparent gray field represents simulation-based 95% confidence intervals for the median. The observed 5th and 95th
percentiles are indicated by dashed lines, and the 95% intervals for the model-predicted percentiles are indicated as corresponding semitransparent gray fields.
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bornswith a PMAof34weeks and 12.5mg/kg for newbornswith a
PMA of 34 weeks given twice daily allowed 90 and 84% of the
patients, respectively, to achieve the AUC/MIC target, with a stan-
dardEUCASTMICsusceptibility breakpoint of 0.5mg/liter (29). For
this optimal dosing regimen, the associated risks of overdose, which
was defined as the simulatedAUCover themaximumreported value
of 291 mg·h/liter, were low (8%), which supports a balanced effi-
cacy and safety profile associated with the recommended dosing reg-
imens. Clearly, organisms with a higherMICwould require a higher
AUC to achieve the same outcome (6, 30). In the United States, the
Clinical Laboratory Standards Institute’s breakpoint is even higher
with a,MICof1mg/liter (31) and, as a consequence, a double dose
(with assumption of linear pharmacokinetics) would be required to
achieve the same AUC/MIC target.
The pharmacokinetic model of ciprofloxacin was developed
and internally validated. External validation was not performed
because of the limited number of patients currently exposed to
this drug. Ultimately, a patient-tailored dose based on modeling
and simulation has to be evaluated in clinical practice to confirm
its clinical benefits.
Conclusion. A population pharmacokinetic model of cipro-
floxacin was developed in neonates and young infants, showing a
low clearance of the drug, compared to older children and adults.
Gestational age at birth, postnatal age, current weight, serum cre-
atinine concentration, and the coadministration of inotropic
agents had significant impact on ciprofloxacin pharmacokinetics.
The ciprofloxacin dosing regimen in neonates and young infants
3 months old was established based on population pharmaco-
kinetics analysis.
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